Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.
Trefny MP, Rothschild SI, Uhlenbrock F, Rieder D, Kasenda B, Stanczak MA, Berner F, Kashyap AS, Kaiser M, Herzig P, Poechtrager S, Thommen DS, Geier F, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz KD, Zippelius A, Läubli H. Trefny MP, et al. Among authors: alborelli i. Clin Cancer Res. 2019 May 15;25(10):3026-3034. doi: 10.1158/1078-0432.CCR-18-3041. Epub 2019 Feb 14. Clin Cancer Res. 2019. PMID: 30765392
Cemento-osseous dysplasia is caused by RAS-MAPK activation.
Haefliger S, Turek D, Andrei V, Alborelli I, Calgua B, Ameline B, Harder D, Baumhoer D. Haefliger S, et al. Among authors: alborelli i. Pathology. 2023 Apr;55(3):324-328. doi: 10.1016/j.pathol.2022.10.006. Epub 2022 Dec 21. Pathology. 2023. PMID: 36707318 Free article.
Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study.
Alborelli I, Generali D, Jermann P, Cappelletti MR, Ferrero G, Scaggiante B, Bortul M, Zanconati F, Nicolet S, Haegele J, Bubendorf L, Aceto N, Scaltriti M, Mucci G, Quagliata L, Novelli G. Alborelli I, et al. Cell Death Dis. 2019 Jul 11;10(7):534. doi: 10.1038/s41419-019-1770-3. Cell Death Dis. 2019. PMID: 31296838 Free PMC article.
Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I, Leonards K, Rothschild SI, Leuenberger LP, Savic Prince S, Mertz KD, Poechtrager S, Buess M, Zippelius A, Läubli H, Haegele J, Tolnay M, Bubendorf L, Quagliata L, Jermann P. Alborelli I, et al. J Pathol. 2020 Jan;250(1):19-29. doi: 10.1002/path.5344. Epub 2019 Oct 24. J Pathol. 2020. PMID: 31471895 Free PMC article.
T cell subtype profiling measures exhaustion and predicts anti-PD-1 response.
Schillebeeckx I, Earls J, Flanagan KC, Hiken J, Bode A, Armstrong JR, Messina DN, Adkins D, Ley J, Alborelli I, Jermann P, Glasscock JI. Schillebeeckx I, et al. Among authors: alborelli i. Sci Rep. 2022 Jan 25;12(1):1342. doi: 10.1038/s41598-022-05474-7. Sci Rep. 2022. PMID: 35079117 Free PMC article.
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
Addeo A, Rothschild SI, Holer L, Schneider M, Waibel C, Haefliger S, Mark M, Fernandez E, Mach N, Mauti L, Jermann PM, Alborelli I, Calgua B, Savic-Prince S, Joerger M, Früh M. Addeo A, et al. Among authors: alborelli i. Lung Cancer. 2022 Oct;172:154-159. doi: 10.1016/j.lungcan.2022.08.016. Epub 2022 Aug 28. Lung Cancer. 2022. PMID: 36099710 Free article. Clinical Trial.
ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.
Eichhoff OM, Stoffel CI, Käsler J, Briker L, Turko P, Karsai G, Zila N, Paulitschke V, Cheng PF, Leitner A, Bileck A, Zamboni N, Irmisch A, Balazs Z, Tastanova A, Pascoal S, Johansen P, Wegmann R, Mena J, Othman A, Viswanathan VS, Wenzina J, Aloia A, Saltari A, Dzung A; TuPro Consortium; Krauthammer M, Schreiber SL, Hornemann T, Distel M, Snijder B, Dummer R, Levesque MP. Eichhoff OM, et al. Cancer Res. 2023 Apr 4;83(7):1128-1146. doi: 10.1158/0008-5472.CAN-22-1826. Cancer Res. 2023. PMID: 36946761
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
Cathomas R, Rothschild SI, Hayoz S, Bubendorf L, Özdemir BC, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel RT, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U. Cathomas R, et al. Among authors: alborelli i. J Clin Oncol. 2023 Nov 20;41(33):5131-5139. doi: 10.1200/JCO.23.00363. Epub 2023 Aug 17. J Clin Oncol. 2023. PMID: 37590894 Free PMC article. Clinical Trial.
39 results